Showing results (171-180 of 432) with videos related to
Sort By:
Pageof 44
Tumori|May 2, 2018
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECISTAlessandro Inno, Giuseppe Lo Russo, Matteo Salgarello, et al.NPJ Digital Medicine|December 23, 2025
ARTEMIS: a pilot study comparing AI-based and expert therapeutic decisions in simulated clinical cases of neuroendocrine neoplasmsGiuseppe Lamberti, Francesco Panzuto, Sara Massironi, et al.Cancers|September 29, 2020
Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined GroupsGiovanni Centonze, Davide Biganzoli, Natalie Prinzi, et al.Journal of Translational Medicine|August 4, 2021
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigatorsMarco Stellato, Giuseppe Procopio, Ugo De Giorgi, et al.Journal of Clinical Medicine|April 2, 2020
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?Alessia Mennitto, Veronica Huber, Raffaele Ratta, et al.Clinical Genitourinary Cancer|January 31, 2024
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or PazopanibMartina Catalano, Ugo De Giorgi, Davide Bimbatti, et al.Cancer Treatment Reviews|November 19, 2023
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature reviewLaurence Albiges, Bradley A McGregor, Daniel Y C Heng, et al.Tumori|October 7, 2024
Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacyAlessandro Rametta, Paolo Ambrosini, Chiara Cavalli, et al.Future Oncology (London, England)|June 6, 2017
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumorsSara Pusceddu, Natalie Prinzi, Giuseppe Lo Russo, et al.Oncology|September 28, 2021
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)Umberto Basso, Giuseppe Procopio, Giuseppe Fornarini, et al.Pageof 44